The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to ...
Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among ...
Researchers found that the common blood pressure drug telmisartan can significantly improve the performance of the cancer ...
The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to ...
Prexasertib, a cell cycle checkpoint kinase 1 inhibitor, in BRCA mutant recurrent high-grade serous ovarian cancer (HGSOC): A proof-of-concept single arm phase II study. A randomized multicenter phase ...
Volume Pledge is Not Associated with Better Short-Term Outcomes After Lung Cancer Resection The risk of disease progression or death was reduced with olaparib compared with placebo by 69% (HR, 0.31; ...
Olaparib plus abiraterone and prednisone or prednisolone already is approved in the European Union and several other countries. The FDA today approved olaparib (Lynparza) when used in combination with ...
Final overall survival (OS) results of the phase III SOLO3 trial show similar outcomes with olaparib versus non–platinum-based chemotherapy in patients with platinum-sensitive BRCA-mutated relapsed ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...
The addition of olaparib (Lynparza) to standard treatment significantly improved disease-free survival (DFS) in patients with early, high-risk HER2-negative breast cancer and germline BRCA mutations, ...
The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results